Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal

Samsung Biologics is acquiring Switzerland's PolyPeptide Group for one point eight billion dollars in an all-cash deal, CNBC reports. PolyPeptide manufactures peptide compounds for pharmaceutical and biotech companies.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton